124 related articles for article (PubMed ID: 34006447)
1. Detection of hepatitis C virus and parvovirus B19 in human plasma pools by nucleic-acid amplification techniques - Trends in results of EDQM proficiency testing studies from 2004 to 2018.
Taconet L; Seifner A; Baylis SA; Chudy M; Kreβ J; Mathys E; Wirz M; Buchheit KH; Behr-Gross ME
Biologicals; 2021 Jun; 71():9-19. PubMed ID: 34006447
[TBL] [Abstract][Full Text] [Related]
2. Collaborative study for establishment of a European Pharmacopoeia Biological Reference Preparation (BRP) for B19 virus DNA testing of plasma pools by nucleic acid amplification technique.
Nübling CM; Daas A; Buchheit KH
Pharmeuropa Bio; 2004 Jan; 2003(2):27-34. PubMed ID: 14960261
[TBL] [Abstract][Full Text] [Related]
3. A proficiency testing study to evaluate laboratory performance for the detection of different genotypes of parvovirus B19.
Baylis SA; Buchheit KH
Vox Sang; 2009 Jul; 97(1):13-20. PubMed ID: 19416495
[TBL] [Abstract][Full Text] [Related]
4. Safety issues for plasma derivatives and benefit from NAT testing.
Willkommen H; Schmidt I; Löwer J
Biologicals; 1999 Dec; 27(4):325-31. PubMed ID: 10686059
[TBL] [Abstract][Full Text] [Related]
5. [Parvovirus B19 DNA testing in Polish blood donors, 2004-2010].
Grabarczyk P; Korzeniowska J; Liszewski G; Kalińska A; Sulkowska E; Krug-Janiak M; Kopacz A; Łetowska M; Brojer E
Przegl Epidemiol; 2012; 66(1):7-12. PubMed ID: 22708291
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of an automated high-volume extraction method for viral nucleic acids in comparison to a manual procedure with preceding enrichment.
Hourfar MK; Schmidt M; Seifried E; Roth WK
Vox Sang; 2005 Aug; 89(2):71-6. PubMed ID: 16101686
[TBL] [Abstract][Full Text] [Related]
7. [Detection of B19 parvovirus in plasma pools before solvent-detergent treatment of plasma: AFSSAPS and EFS Aquitaine-Limousin's experience].
Petermann R; Piquet Y; Lapeyre M; Goujon N; Gauthier M; Lalanne V; Mouillot L; Tissier MH; Boiron JM
Transfus Clin Biol; 2010 Apr; 17(2):54-62. PubMed ID: 20674438
[TBL] [Abstract][Full Text] [Related]
8. Multicenter evaluation of a commercial multiplex polymerase chain reaction test for screening plasma donations for parvovirus B19 DNA and hepatitis A virus RNA.
Koppelman MH; Cuijpers HT; Wessberg S; Valkeajärvi A; Pichl L; Schottstedt V; Saldanha J
Transfusion; 2012 Jul; 52(7):1498-508. PubMed ID: 22587637
[TBL] [Abstract][Full Text] [Related]
9. Collaborative study to assess the suitability of a proposed working reagent for human parvovirus B19 DNA detection in plasma pools by gene amplification techniques. B19 Collaborative Study Group.
Saldanha J; Minor P
Vox Sang; 1997; 73(4):207-11. PubMed ID: 9407637
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of human parvovirus B19 in Chinese plasma pools for manufacturing plasma derivatives.
Jia J; Ma Y; Zhao X; Guo Y; Huangfu C; Fang C; Fan R; Lv M; Yin H; Zhang J
Virol J; 2015 Oct; 12():162. PubMed ID: 26445095
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of two, commercial, multi-dye, nucleic acid amplification technology tests, for HBV/HCV/HIV-1/HIV-2 and B19V/HAV, for screening blood and plasma for further manufacture.
Müller MM; Fraile MI; Hourfar MK; Peris LB; Sireis W; Rubin MG; López EM; Rodriguez GT; Seifried E; Saldanha J; Schmidt M
Vox Sang; 2013 Jan; 104(1):19-29. PubMed ID: 23252689
[TBL] [Abstract][Full Text] [Related]
12. Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virus.
Bonvicini F; Gallinella G; Cricca M; Ambretti S; Delbarba S; Musiani M; Zerbini M
J Med Virol; 2004 Oct; 74(2):272-6. PubMed ID: 15332276
[TBL] [Abstract][Full Text] [Related]
13. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma.
Baylis SA; Shah N; Minor PD
J Virol Methods; 2004 Oct; 121(1):7-16. PubMed ID: 15350727
[TBL] [Abstract][Full Text] [Related]
15. Quantitative real-time detection of parvovirus B19 DNA in plasma.
Koppelman MH; Cuypers HT; Emrich T; Zaaijer HL
Transfusion; 2004 Jan; 44(1):97-103. PubMed ID: 14692974
[TBL] [Abstract][Full Text] [Related]
16. Standardization: a progress report.
Saldanha J
Biologicals; 1999 Dec; 27(4):285-9. PubMed ID: 10686054
[TBL] [Abstract][Full Text] [Related]
17. Magnetic bead technology in viral RNA and DNA extraction from plasma minipools.
Pichl L; Heitmann A; Herzog P; Oster J; Smets H; Schottstedt V
Transfusion; 2005 Jul; 45(7):1106-10. PubMed ID: 15987354
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the prevalence of human parvovirus B19 DNA in Korean plasmapheresis donors.
Oh DJ; Lee YL; Kang JW; Kwon SY; Cho NS
Korean J Lab Med; 2010 Feb; 30(1):58-64. PubMed ID: 20197724
[TBL] [Abstract][Full Text] [Related]
19. Standardization of nucleic acid amplification technique (NAT)-based assays for different genotypes of parvovirus B19: a meeting summary.
Baylis SA
Vox Sang; 2008 Jan; 94(1):74-80. PubMed ID: 18171331
[TBL] [Abstract][Full Text] [Related]
20. Decreasing parvovirus B19 and hepatitis A nucleic acid test positivity rates in Canadian plasma donors following the initiation of COVID-19 restriction in March 2020.
Drews SJ; Charlton C; O'Brien SF; Burugu S; Denomme GA
Vox Sang; 2024 Jun; 119(6):624-629. PubMed ID: 38482941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
